HIV coinfection with hepatitis c pathophysiology

HIV coinfection with hepatitis c Microchapters

Home

Patient Information

Overview

Pathophysiology

Causes

Differentiating HIV coinfection with hepatitis c from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

HIV coinfection with hepatitis c pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of HIV coinfection with hepatitis c pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on HIV coinfection with hepatitis c pathophysiology

CDC on HIV coinfection with hepatitis c pathophysiology

HIV coinfection with hepatitis c pathophysiology in the news

Blogs on HIV coinfection with hepatitis c pathophysiology

Directions to Hospitals Treating HIV coinfection with hepatitis c

Risk calculators and risk factors for HIV coinfection with hepatitis c pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

## Pathophysiology[edit | edit source]

HIV’s effect on Hepatitis C: Studies have shown that HIV infection in a person who is also infected with HCV results in higher levels of HCV in the blood, more rapid progression to HCV-related liver disease, and increased risk for cirrhosis and liver cancer. As a result, HCV is now regarded as an opportunistic infection in people with HIV infection, although it is not considered an AIDS-defining illness.

HCV’s effect on HIV: Some research suggests that infection with genotype 1 HCV is associated with more rapid progression to AIDS or death, although this is still controversial. Most people with HCV infection in the U.S. have genotype 1. Genotypes 2 and 3 are more common in Europe. Some evidence also indicates that HCV is associated with impaired CD4+ T cell recovery during antiretroviral therapy.

## References[edit | edit source]